AlexanderNoorShoushtariMD

PubMed

• Clearance of plasma cell free DNA in metastatic uveal melanoma with radiographic response to immune checkpoint inhibitors.
  Jasmine H Francis, Christopher A Barker, Julia Canestraro, David H Abramson, Alexander N Shoushtari> ;American Journal of Ophthalmology Case Reports. 2024 Jun 1
• Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.
  Paul B Chapman, Mark Klang, Michael A Postow, Ryan J Sullivan, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K Callahan, Bin Zheng, Shoushtari, A., Zippin, J., Wo...> ;Cancer Research Communications. 2023 Dec 4
• 1 citations
  The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
  Adriana Hepner, Judith M Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojaniello, Camille Lea Gerard, Yanina Jl Jansen, Prachi Bhave, Bart Ne...> ;European Journal of Cancer. 2024 Jan 1
• 4 citations
  Most large structural variants in cancer genomes can be detected without long reads.
  Zi-Ning Choo, Julie M Behr, Aditya Deshpande, Kevin Hadi, Xiaotong Yao, Huasong Tian, Kaori Takai, George Zakusilo, Joel Rosiene, Arnaud Da Cruz Paula, Britta Weigelt,...> ;Nature Genetics. 2023 Dec 1
• 1 citations
  Determinants of overall survival in patients with metastatic uveal melanoma.
  Patrick Demkowicz, Renelle Pointdujour-Lim, Sofia Miguez, Yesung Lee, Bailey S C L Jones, Christopher A Barker, Marcus Bosenberg, David H Abramson, Alexander N Shousht...> ;Cancer. 2023 Oct 15
• Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
  Omid Hamid, Jessica C Hassel, Alexander N Shoushtari, Friedegund Meier, Todd M Bauer, April K S Salama, John M Kirkwood, Paolo A Ascierto, Paul C Lorigan, Cornelia Mau...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
• Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
  Kimberly Loo, Hannah L Kalvin, Katherine S Panageas, Margaret K Callahan, Paul B Chapman, Parisa Momtaz, Alexander N Shoushtari, Michael A Postow, Allison Betof Warner...> ;Pigment Cell & Melanoma Research. 2023 Apr 11
• 2 citations
  Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
  Israel S Kasago, Walid K Chatila, Cecilia M Lezcano, Christopher A Febres-Aldana, Nikolaus Schultz, Chad Vanderbilt, Snjezana Dogan, Edmund K Bartlett, Sandra P D'Ange...> ;Modern Pathology. 2023 Aug 1
• 1 citations
  Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
  Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross, Carlos Torres-Cabala, Isabella C Glitza, Fei Duan, Denái R Milton, Klaus Busam...> ;Nature. 2023 Mar 1
• 1 citations
  More than Just Skin-Deep: A Review of Imaging's Role in Guiding CAR T-Cell Therapy for Advanced Melanoma.
  Conor M Prendergast, Kathleen M Capaccione, Egesta Lopci, Jeeban P Das, Alexander N Shoushtari, Randy Yeh, Daniel Amin, Laurent Dercle, Dorine De Jong> ;Diagnostics. 2023 Mar 5
• 4 citations
  Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
  Thomas M Atkinson, Jennifer L Hay, Soo Young Kim, Elizabeth Schofield, Michael A Postow, Parisa Momtaz, Allison Betof Warner, Alexander N Shoushtari, Margaret K Callah...> ;The Oncologist. 2023 Apr 6
• Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to t...
  Jeffrey S Weber, Tayla Poretta, Brian D Stwalley, Leon A Sakkal, Ella X Du, Travis Wang, Yan Chen, Yan Wang, Keith A Betts, Alexander N Shoushtari> ;Cancer Immunology, Immunotherapy. 2023 Apr 1
• 4 citations
  Detectability of Plasma-Derived Circulating Tumor DNA Panel in Patients Undergoing Primary Treatment for Uveal Melanoma.
  Jasmine H Francis, Christopher A Barker, A Rose Brannon, Julia Canestraro, Melissa Robbins, Christina E Swartzwelder, Sara Levine, Crystal Law, Michael F Berger, Alexa...> ;Investigative Ophthalmology & Visual Science. 2022 Dec 1
• 99 citations
  Neoadjuvant relatlimab and nivolumab in resectable melanoma.
  Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross, Carlos Torres-Cabala, Isabella C Glitza, Fei Duan, Denái R Milton, Klaus Busam...> ;Nature. 2022 Nov 1
• 39 citations
  Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
  Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel, Alexandra Ikeguchi, Leonel Hernandez-Aya, Paul Nathan, Omid Hamid, Josep M Piulats, Matt...> ;Nature Medicine. 2022 Nov 1
• 1 citations
  Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis f...
  Jeffrey S Weber, Tayla Poretta, Brian D Stwalley, Leon A Sakkal, Ella X Du, Travis Wang, Yan Chen, Yan Wang, Keith A Betts, Alexander N Shoushtari> ;Cancer Immunology, Immunotherapy. 2023 Apr 1
• 17 citations
  Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.
  Alexander N Shoushtari, Anthony J Olszanski, Marta Nyakas, Thomas J Hornyak, Victor Levitsky, Lukasz Kuryk, Thomas B Hansen, Magnus Jäderberg, Wolchok, J.> ;Clinical Cancer Research. 2023 Jan 4
• 5 citations
  Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
  Seungyeon Jung, Emma Armstrong, Alexander Z Wei, Fei Ye, Aaron Lee, Matteo S Carlino, Ryan J Sullivan, Richard D Carvajal, Alexander N Shoushtari, Douglas B Johnson> ;British Journal of Cancer. 2022 Nov 1
• 7 citations
  Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy.
  Catherine Young Han, Conall Fitzgerald, Mark Lee, Cristina Valero, Mithat Gönen, Alexander Shoushtari, Luc G T Morris> ;JAMA Oncology. 2022 Sep 1
• 17 citations
  Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
  Prachi Bhave, Tasnia Ahmed, Serigne N Lo, Alexander Shoushtari, Anne Zaremba, Judith M Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline...> ;Journal for Immunotherapy of Cancer. 2022 Jul 1
• 17 citations
  Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
  F Dimitriou, K Namikawa, I L M Reijers, E I Buchbinder, J A Soon, A Zaremba, P Teterycz, M J Mooradian, E Armstrong, Y Nakamura, M G Vitale, L E Tran, X Bai, C Allayou...> ;Annals of Oncology. 2022 Sep 1
• Combination intravitreous melphalan and bevacizumb for cutaneous metastatic melanoma to the vitreous and retina.
  Jasmine H Francis, Julia Canestraro, David H Abramson, Christopher A Barker, Alexander N Shoushtari> ;American Journal of Ophthalmology Case Reports. 2022 Jun 1
• 11 citations
  Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma.
  Lukas Kraehenbuehl, Aliya Holland, Emma Armstrong, Sirinya O'Shea, Levi Mangarin, Sara Chekalil, Amanda Johnston, John S Bomalaski, Joseph P Erinjeri, Christopher A Ba...> ;Cancers. 2022 May 26
• 6 citations
  Specific human endogenous retroviruses predict metastatic potential in uveal melanoma.
  Matthew L Bendall, Jasmine H Francis, Alexander N Shoushtari, Douglas F Nixon> ;JCI Insight. 2022 May 9
• 16 citations
  Deciphering radiological stable disease to immune checkpoint inhibitors.
  J Luo, S Wu, H Rizvi, Q Zhang, J V Egger, J C Osorio, A J Schoenfeld, A J Plodkowski, M S Ginsberg, M K Callahan, C Maher, A N Shoushtari, M A Postow, M H Voss, R R Ko...> ;Annals of Oncology. 2022 Aug 1
• Join now to see all

Lectures

• Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas. 
  2019 ASCO Annual Meeting - 6/1/2019
• Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018